A cold atmospheric plasma (CAP)-mediated ICB therapy/delivery device are disclosed herein that employs a patch having microneedles that are used to deliver the CAP transdermally along with an immune checkpoint inhibitor for enhancing transdermal treatment efficacy. The hollow-structured microneedle patch can facilitate the transportation of CAP through the skin, causing tumor cell death. The release of cancer antigens then promotes the maturation of dendritic cells in the tumor-draining lymph nodes, subsequently initiating the T cell-mediated immune response. Anti-PDL1 antibody (aPDL1), an immune checkpoint inhibitor (or other immune checkpoint inhibitors), released from the microneedle patch (in some embodiments) further augments the anti-tumor immunity. The transdermal combinational CAP and ICB therapy inhibits tumor growth for both primary tumors as well as distant tumors, with prolonged survival in the tumor-bearing mice. Such results should translate to other species.

The present invention relates to extended release compositions of an amino-C2-C6-alkyl nitrate and of pharmaceutically acceptable salt thereof, in particular 2-aminoethyl nitrate, and to fixed dose combinations with further pharmaceutically active drug substances. 2-Aminoethyl nitrate does not provoke nitrate tolerance, but has a very short half life in physiological systems.

In some aspects, the present disclosure provides pharmaceutical compositions comprising a) a therapeutic agent; b) a metal-organic framework (MOF) or a coordination polymer; and c) a pharmaceutically acceptable polymer; wherein the therapeutic agent is encapsulated within the metal-organic framework or coordination polymer to form an encapsulated therapeutic agent, and wherein the encapsulated therapeutic agent is further encapsulated, entrapped, embedded, dispersed within, or complexed to the pharmaceutically acceptable polymer. The present disclosure also provides methods of making said compositions, methods of treating a disease or disorder comprising administering to a subject said compositions. The present disclosure also provides microneedles and implantable medical devices comprising said compositions.

A nanofibrous mat comprising: electrospun nanofibres forming said mat; and ceramic particles dispersed throughout said nanofibres and comprising a ceramic matrix and a dopant releasably encapsulated within said ceramic matrix, wherein the ceramic particles are dispersed throughout the nanofibres during electrospinning of the nanofibres, whereby said dopant is protected by said ceramic matrix during said electrospinning.

The invention relates to methods for treatment of bone fractures and defects, in particular to method that accelerate fracture healing, and to compositions, injectable in situ depot forming formulations and patches comprising at least one biodegradable polymer, an androgen receptor agonist and a bisphosphonate or pharmaceutically acceptable salt thereof for use in such methods.

The disclosed adhesive medical article has a backing layer having a first major surface and a second major surface opposite to the first major surface. The backing layer has a central portion and an outer circumferential portion. The article further has a pressure sensitive adhesive pattern coating applied onto at least part of the first major surface of the backing layer in such a way as to form a plurality of adhesive coated and adhesive uncoated areas of the backing layer. The adhesive uncoated areas comprise a central collection portion and at least one longitudinal extension radiating from the central collection portion towards the outer circumferential portion of the backing layer.

A patch for at least partially reducing at least one of pain, swelling, inflammation and irritation in at least one body part of a user is provided. The patch includes at least one cloth layer having the propolis composition embedded therein. The patch includes a first plastic layer disposed immediately against a first side of the at least one cloth layer, and a second plastic layer disposed immediately against a second side of the at least one cloth layer opposite the first side, such that the at least one cloth layer is sandwiched between the first and second plastic layers. The propolis composition is configured to at least partially reduce at least one of perceived pain, swelling, inflammation and irritation when the patch is applied to the at least one body part. Related methods of use and/or manufacture for such a patch are also provided.

A method for creating a consolidated compound for delivering an immunomodulatory and imiquimod to a patient, comprising diluting immunomodulator extract to a desired dilution by transferring a desired quantity of the concentrated immunomodulator to an associated sterile container, the associated sterile container having a defined volume of diluted immunomodulator after dilution thereof, providing a viscous encapsulation material, selecting a prescribed amount of concentrated immunomodulator, the prescribed amount defined as that amount of the diluted immunomodulator extract required to provide a number of doses equal to the number of dispensable increments from the container containing the viscous encapsulation material, introducing the selected amount of each of the diluted immunomodulator extract into the viscous encapsulation material, introducing an amount of imiquimod into the viscous encapsulation material, and mixing the introduced amount of each of the diluted immunomodulator extracts and the introduced amount of imiquimod with the viscous encapsulating material.

An adhesive patch comprising: a support; at least a pressure-sensitive adhesive layer provided on the support; and a release liner attached on the pressure-sensitive adhesive layer so as to cover the surface of the pressure-sensitive adhesive layer, in which the support is a 3D patterned sheet characterized in that a plurality of protruded lines and recessed lines parallelly and linearly extending are formed inside and outside lines in a plurality of figures partitioned by the lines, walls of the protruded lines and recessed lines in some of the figures are formed to be inclined by different inclination angles with respect to a base part, and the protruded lines have different heights from the base part, serving as physical parameters of the protruded lines and recessed lines, toward a predetermined direction in the sheet.

To provide a transdermal drug delivery patch that can be suitably used for an immediate release application of a pharmaceutical with a comparatively low molecular weight. A transdermal drug delivery patch, provided with a matrix and at least one drug disposed within the matrix, wherein the matrix has a water holding capacity of 10 mg/cm.sup.2 or less, and the drug is a pharmaceutical having a molecular weight of 5000 or less.